Abstract

The Cooper Companies, Inc. will report results on September 9, 2026 Post-Mkt; consensus points to revenue near 1.10 billion US dollars and adjusted EPS around 1.12, with investor focus on margin trajectory, any updates to one-off charges, and reinforcement of guidance for fiscal-year profitability.

Market Forecast

Consensus for the current quarter calls for revenue of 1.10 billion US dollars, up 3.24% year over year, and adjusted EPS of 1.12, up 4.60% year over year; EBIT is projected at 277.03 million US dollars, up 0.87% year over year. Forecasts do not provide a gross profit margin or net profit margin for this quarter. The main business is expected to remain anchored by CooperVision’s premium lens mix and steady demand across core modalities, while company commentary and consensus imply incremental EBIT stability against a tough comparison. CooperVision remains the primary contributor with 723.50 million US dollars last quarter, and CooperSurgical contributed 358.00 million US dollars; among the segments, the strongest near-term upside is expected from premium, higher-value vision products that sustain mix-led revenue growth, though year-over-year segment breakouts are not disclosed in the dataset.

Last Quarter Review

The Cooper Companies, Inc. delivered last quarter revenue of 1.08 billion US dollars (up 7.90% year over year), a gross profit margin of 68.00%, a GAAP net loss attributable to shareholders of 77.90 million US dollars, a net profit margin of -7.20%, and adjusted EPS of 1.21 (up 26.04% year over year). A key highlight was an operating outperformance versus expectations: EBIT reached 297.20 million US dollars, above the 275.66 million US dollars consensus, and adjusted EPS of 1.21 exceeded the 1.096 estimate, indicating robust operating momentum despite below-the-line items that produced a GAAP loss. Main business dynamics showed CooperVision at 723.50 million US dollars and CooperSurgical at 358.00 million US dollars, with the mix implying 66.90% and 33.10% of total revenue respectively in the quarter; quarter-on-quarter, the net profit change rate was -159.56%, underscoring the impact of non-operating or non-cash items in the GAAP line.

Current Quarter Outlook

CooperVision: core performance path this quarter

CooperVision’s contribution remains the linchpin for this quarter’s earnings construct. The company ended the prior quarter with a 68.00% gross margin and a robust adjusted EPS beat, suggesting that pricing, mix, and efficiency gains in the lens portfolio supported operating leverage even as GAAP net income was constrained by one-off or non-operating charges. With consensus revenue growth of 3.24% and adjusted EPS growth of 4.60% for the current quarter, the implied setup anticipates continued resilience from higher-value products within the CooperVision portfolio, which is consistent with the segment’s scale and profitability profile observed in the prior quarter. Within the quarter, investor attention will be on the sustainability of the premium lens mix and the degree of operating discipline that preserves EBIT despite modest top-line growth. Inventory and channel normalization also matter for modeling gross-to-net performance, because small changes in channel flow-through can influence reported growth in a low-single-digit revenue quarter. Foreign exchange can introduce noise; however, the prior quarter’s outperformance on EBIT indicates the company had operational levers—cost control and mix—that cushioned variability, and similar levers are likely to be emphasized this quarter. Gross margin direction is a key data point that can validate or challenge the earnings bridge from revenue to EPS. Though the forecast dataset does not include an explicit gross margin for the current quarter, last quarter’s 68.00% level provides a reference; if management signals stable manufacturing yields and product mix, investors will infer a path for margin that aligns with achieving the 1.12 adjusted EPS consensus. Any unexpected changes to rebates, promotional cadence, or raw-material and logistics costs could nudge gross margin, but the operating track record in the prior quarter sets a constructive baseline for this release.

CooperSurgical: recovery path and earnings sensitivity

CooperSurgical contributed 358.00 million US dollars last quarter and represented roughly one-third of company revenue. The quarter’s negative GAAP net result, contrasted with strong EBIT, implies below-the-line impacts that could have intersected with this segment as well as corporate items; for investors, the near-term focus turns to whether those impacts are fully recognized or continue to drift into the P&L. A clean quarter, with minimal special items, would allow the operating performance to flow-through to GAAP metrics and, by extension, reduce volatility around net margin. This quarter, monitoring revenue quality in CooperSurgical is essential: mix within fertility-related and women’s health offerings can alter both revenue timing and margin capture. Steady-order cadence and consistent pricing would support EBIT stability, aligning with the 277.03 million US dollars consensus for this quarter’s EBIT. The segment’s contribution to consolidated growth need not be large for EPS to meet consensus, provided execution avoids new one-off charges and the operating structure remains efficient. From a valuation perspective, a demonstration of sequential normality—modest revenue growth, balanced opex, and absence of additional non-operating charges—could be just as important as headline growth. If CooperSurgical prints in line with its revenue base and the consolidated EBIT aligns with consensus, it would underpin the 4.60% forecast expansion in adjusted EPS. Any constructive commentary on order trends, backlog conversion, or margin cadence within the segment would help investors refine second-half models without requiring substantial top-line acceleration.

Key stock-price drivers this quarter

The most proximate driver is the translation of a 3.24% revenue growth outlook into the projected 1.12 adjusted EPS, which requires confirmation of expense control and margin hold. Because last quarter’s GAAP net margin was -7.20% despite operational beats, investors are sensitive to the presence or absence of special items that could again depress GAAP results; a clean GAAP print would likely narrow the dispersion of post-release estimates. Management’s commentary on quarterly expense cadence, particularly in SG&A and any legal or other non-operating lines, will be pivotal to assess sustainability of earnings power into the fiscal year-end. Another driver is the trajectory of EBIT. The last quarter delivered EBIT of 297.20 million US dollars versus a 275.66 million US dollars estimate, while the current quarter forecast stands at 277.03 million US dollars, up 0.87% year over year. If EBIT lands near or above that level, it would substantiate the internal leverage assumed in models and bolster confidence in the mid-year run rate. By contrast, if EBIT softness emerges, investors will press for explanations around mix, one-off costs, or timing-related dynamics. Finally, capital allocation signals can influence the stock reaction. While no explicit guidance is included in the dataset, investors commonly watch for updates related to buyback activity, capital expenditures, or changes to full-year outlook that align with consensus assumptions. Given that last quarter’s results were greeted positively by the market in after-hours trading based on reports of a beat, reiteration of a consistent operating message while clearing GAAP volatility would reinforce the current consensus narrative and dampen downside scenarios.

Analyst Opinions

Bullish-to-bearish ratio over the last six months stands at 100% bullish and 0% bearish among the collected views. Piper Sandler reiterated a Buy on The Cooper Companies, Inc., signaling confidence that the premium lens mix and disciplined cost structure can carry adjusted EPS higher, even as revenue growth remains modest in the near term; the firm’s stance aligns with consensus forecasts that show 3.24% revenue growth and 4.60% adjusted EPS growth this quarter. William Blair also maintained a Buy view, referencing an expected continuation of margin expansion and EPS progression supported by premium product penetration and stable operating execution. The bullish consensus coalesces around three pillars. First, last quarter’s operating beat—EBIT of 297.20 million US dollars versus a 275.66 million US dollars estimate and adjusted EPS of 1.21 versus 1.096—demonstrated controllable drivers in mix and cost that can be replicated, lending credibility to a 1.12 adjusted EPS forecast this quarter. Second, analysts expect CooperVision’s scaling franchise to maintain revenue leadership and provide a more predictable gross margin contribution, given the prior quarter’s 68.00% gross margin baseline; this provides a cushion for adjusted EPS if other items remain stable. Third, the expectation for a cleaner GAAP result, absent the prior quarter’s non-operating headwinds, underpins the potential for a narrower spread between adjusted and GAAP outcomes, which in turn supports sentiment and reduces model risk. Plausible upside scenarios within the bullish framework include a revenue print near 1.10 billion US dollars accompanied by in-line-to-better EBIT and a reiteration of expense control measures. Under such a setup, the spread between adjusted EPS and GAAP results could compress, thereby improving comparability and enabling analysts to raise confidence in out-year margins. Bullish views also emphasize that if premium product momentum persists within CooperVision and CooperSurgical delivers a stable contribution without fresh special items, consensus for low- to mid-single-digit revenue growth with expanding earnings could remain intact into subsequent quarters. The buy-side sensitivity is nevertheless tuned to gross margin footprints and any updates about non-operating items. Analyst discussions highlight that repeating last quarter’s operating discipline is more important than achieving outsized top-line beats in a quarter with 3.24% expected growth. In essence, the majority view expects steady execution, confirms that the prior quarter’s GAAP gap was episodic rather than structural, and sees the risk-reward supported by the capacity to deliver consistent adjusted EPS in the 1.12 range while preserving leverage for the fiscal year’s back half.